Original Article

Estimated number of N95 respirators needed for healthcare workers in acute-care hospitals during the coronavirus disease 2019 (COVID-19) pandemic

Patrick T. Wedlock MSPH¹, Kelly J. O’Shea BSFS², Madellena Conte MS², Sarah M. Bartsch MPH³, Samuel L. Randall BS¹, Marie C. Ferguson MSPH⁴, Sarah N. Cox MSPH¹, Sheryl S. Siegmund MS¹, Sarah Kulkarni MPH², Denis Nash PhD², Michael Y. Lin MD, MPH³ and Bruce Y. Lee MD, MBA¹

¹Public Health Informatics, Computational, and Operations Research, CUNY Graduate School of Public Health and Health Policy, New York City, New York, ²Institute for Implementation Science in Population Health, City University of New York, New York City, New York and ³Division of Infectious Diseases, Department of Medicine, Rush University Medical Center, Chicago, Illinois

Abstract

Objective: Due to shortages of N95 respirators during the coronavirus disease 2019 (COVID-19) pandemic, it is necessary to estimate the number of N95s required for healthcare workers (HCWs) to inform manufacturing targets and resource allocation.

Methods: We developed a model to determine the number of N95 respirators needed for HCWs both in a single acute-care hospital and the United States.

Results: For an acute-care hospital with 400 all-cause monthly admissions, the number of N95 respirators needed to manage COVID-19 patients admitted during a month ranges from 113 (95% interpercentile range [IPR], 50–229) if 0.5% of admissions are COVID-19 patients to 22,101 (95% IPR, 5,904–25,881) if 100% of admissions are COVID-19 patients (assuming single use per respirator, and 10 encounters between HCWs and each COVID-19 patient per day). The number of N95s needed decreases to a range of 22 (95% IPR, 10–43) to 4,445 (95% IPR, 1,975–8,684) if each N95 is used for 5 patient encounters. Varying monthly all-cause admissions to 2,000 requires 6,645–13,404 respirators with a 60% COVID-19 admission prevalence, 10 HCW–patient encounters, and reusing N95s 5–10 times.

Nationally, the number of N95 respirators needed over the course of the pandemic ranges from 86 million (95% IPR, 37.1–200.6 million) to 1.6 billion (95% IPR, 0.7–3.6 billion) as 5%–90% of the population is exposed (single-use). This number ranges from 17.4 million (95% IPR, 7.3–41 million) to 312.3 million (95% IPR, 131.5–737.3 million) using each respirator for 5 encounters.

Conclusions: We quantified the number of N95 respirators needed for a given acute-care hospital and nationally during the COVID-19 pandemic under varying conditions.

(Received 17 September 2020; accepted 22 December 2020)

Due to persistent and widespread shortages of N95 respirators during the ongoing coronavirus disease 2019 (COVID-19) pandemic in the United States, there is a need to estimate the number of N95 respirators that may be needed for frontline healthcare workers (HCWs) interacting with hospitalized COVID-19 patients. N95 respirators are a crucial component of infection control strategies that minimize HCW exposure to airborne particles and prevent droplets from coming into contact with the mouth and nose.¹ However, many factors, including a dwindling national stockpile and a constrained manufacturing and supply chain capacity,² have resulted in shortages of N95 respirators. Ensuring an adequate supply of respirators for frontline HCWs requires understanding the potential demand, which is dependent on how many people are exposed to COVID-19 coronavirus, how many of those exposed are subsequently hospitalized, and how long each patient remains in the hospital. In addition, varying respirator usage guidelines and patient encounters may alter how many respirators are ultimately needed.

Knowing the number of respirators needed in advance is essential for setting and achieving procurement targets and allocating respirators appropriately. For example, hospital administrators can plan ahead to order enough respirators to adequately cover all HCWs (and other essential personnel), while government...
officials and manufacturers can work together to ensure that production and financing of respirators is adequate to cover even the worst-case scenario. Although past research has estimated the potential demand for N95 respirators under certain assumptions, studies have not demonstrated how these estimates vary when different proportions of the population become exposed and under different operating conditions (eg, number of uses per respirator). Therefore, we developed a computational model to estimate how many N95 respirators would be needed both in a single acute-care hospital, varying with the number of COVID-19 admissions per month, and across the United States over the entire course of the pandemic when different proportions of the population are exposed to severe acute respiratory coronavirus 2 (SARS-CoV-2).

Methods

Single acute-care hospital model

Using Excel software (Microsoft, Redmond, WA) with the Crystal Ball add-in (Oracle, Redwood Shore, CA), we developed a computational model representing a single acute-care hospital to simulate the number of all-cause admissions and what can happen to each person who is hospitalized with confirmed or suspected SARS-CoV-2. For each simulation run, we first determined the number of confirmed and suspected COVID-19 admissions for a single acute-care hospital in a month. To determine the number of confirmed COVID-19 admissions in a month, we applied a COVID-19 prevalence among hospitalized patients to the number of all-cause admissions in that month. Each hospitalized COVID-19–positive patient then travels through a probability tree of different possible sequential clinical outcomes. First, the patient has a probability of having either severe pneumonia or severe nonpneumonia symptoms and has a probability of intensive care unit (ICU) admission. If admitted to the ICU, the patient has a probability of requiring a ventilator, representing acute respiratory distress syndrome (ARDS). The patient also has a probability of dying from COVID-19 complications. Each suspected COVID-19 patient who is later confirmed not to be infected (ie, COVID-19 negative), referred to as persons under investigation (PUI), remains under COVID-19 precautions for 1–2 days, accounting for test turnaround time. We assumed a ratio of 1–2 PUIs for every 10 patients hospitalized with COVID-19.

We assumed that N95 respirators are reserved for interactions between HCWs and hospitalized patients with a suspected or confirmed COVID-19 infection. Each hospitalized COVID-19 patient has 10 encounters per day with HCWs including doctors, nurses, and other staff for the duration of their hospital stay and can include repeated interactions with the same HCW multiple times. As hospitalized patients with more severe disease may require more frequent interactions with HCW, we ran additional scenarios in which patients in the ICU were visited more often per day than patients hospitalized in the general ward. HCW’s dispose of an N95 respirator after one COVID-19 patient encounter, per N95 respirator manufacturer guidelines. These values vary in sensitivity analyses.

US national model

We also developed a model representing the US population (327,167,434 persons) and what can happen to each person who gets infected with SARS-CoV-2 to determine the number of N95 respirators required for the entire United States over the course of the pandemic. This involved determining the percentage of the national population that becomes infected (ie, the attack rate) with the age distribution of cases matching the reported age distribution of COVID-19 cases. Each infected person then travels through a probability tree of different possible sequential clinical outcomes. First, the person has a probability of being asymptomatic throughout the entire course of the infection. If the person is symptomatic (ie, COVID-19 case), he or she starts with a mild infection and has a probability of seeking ambulatory care or calling a physician (ie, telephone consult). This person then has a probability of progressing to severe disease requiring hospitalization. If the person is hospitalized, he or she travels through the clinical progression of hospitalized patients as described above. The number of N95 respirators needed are calculated as described above, but for all COVID-19 hospital admissions.

Results

N95 respirators needed for COVID-19 admissions per month in a single acute-care hospital

Figure 1 shows how changes in the prevalence of COVID-19 among hospital admissions per month influences the number of N95 respirators needed for a single acute-care hospital. For example, in a hospital with 50 all-cause admissions per month, the number of respirators needed for COVID-19 admissions that month (ie, all confirmed COVID-19 patients and PUI) ranges from 820 (95% IPR, 381–1,674) to 1,667 (95% IPR, 798–3,498) with a prevalence of COVID-19 among admissions of 30% to 60%, assuming respirators are disposed after each use and there are 10 encounters per day between HCWs and COVID-19 patients. A hospital averaging 400 all-cause admissions per month would require 6,580 (95% IPR, 3,033–12,918) to 13,378 (95% IPR, 5,695–27,095) N95 respirators.

Data sources

Table 1 shows key model input parameters, values, and sources. All clinical probabilities and durations are age-specific when available and come from scientific literature or nationally representative data sources. Age-specific COVID-19 data are specific to the US context as of May 30, 2020.

Scenarios and sensitivity analyses

Experiments consisted of Monte Carlo simulations of 2,000 trials, varying parameters throughout their range (Table 1). The first set of experiments simulated what may happen to a hospital as the COVID-19 prevalent among patient admissions increases from 0.5% to 100%, varying with the number of all-cause hospital admissions per month (50–2,000). The second set of experiments simulated what may happen nationally over the course of a pandemic as the attack rate increases from 5% to 90%. Different scenarios represent what may happen under varying respirator usage guidelines, that is, the number of patient encounters for which a given respirator can be used (1–20), and when varying the number of encounters each patient has with HCW and staff over the course of 24 hours (total for all staff, 5–20). We also varied the frequency at which HCWs interact with ICU patients compared to general ward patients (2–4 times more frequently). Sensitivity analyses varied key parameters including the distributions of patients’ length of stay (eg, ±50% current values), and the probability of different COVID-19 outcomes (eg, probability of hospitalization, ICU admission, and ventilator use). We report results as the median and the 95% percentile range (IPR) from 2.5 to 97.5.
Table 1. Model Input Parameters, Values, and Sources

| Parameter                                           | Distribution Type | Mean or Median | Standard Error or Range | Source                      |
|-----------------------------------------------------|-------------------|----------------|-------------------------|-----------------------------|
| **Probabilities**                                   |                   |                |                         |                             |
| Asymptomatic infection                              | Triangular        | 0.35           | 0.315–0.385\(^b\)      | CDC\(^21\)                 |
| Relative infectiousness of asymptomatic infection   | Point estimate    | 1              | ...                     | CDC\(^21\)                 |
| Missing work/school                                 | Point estimate    | 1.0            | ...                     | Assumption                 |
| **Ambulatory care**                                 |                   |                |                         |                             |
| 0–4 y                                               | Beta              | 0.455\(^a\)    | 0.098                   | Molinari et al\(^22\)      |
| 5–17 y                                              | Beta              | 0.318\(^a\)    | 0.061                   | Molinari et al\(^22\)      |
| 18–64 y                                             | Beta              | 0.313\(^a\)    | 0.014                   | Molinari et al\(^22\)      |
| ≥65 y                                               | Beta              | 0.62\(^a\)     | 0.027                   | Molinari et al\(^22\)      |
| **Probability of hospitalization, given infection** |                   |                |                         |                             |
| 0–17 years old                                      | Beta Pert         | 0.031          | 0.028-0.034\(^b\)       | Stokes et al\(^23\)        |
| 18–44 years old                                     | Beta Pert         | 0.056          | 0.051-0.062\(^b\)       | Stokes et al\(^23\)        |
| 45–64 years old                                     | Beta Pert         | 0.140          | 0.126-0.154\(^b\)       | Stokes et al\(^23\)        |
| ≥65 years old                                       | Beta Pert         | 0.300          | 0.270-0.330\(^b\)       | Stokes et al\(^23\)        |
| **Probability of ICU admission**                    |                   |                |                         |                             |
| 0–17 y                                              | Beta Pert         | 0.171          | 0.154-0.1881\(^b\)      | Stokes et al\(^23\)        |
| 18–44 y                                             | Beta Pert         | 0.152          | 0.137-0.1675\(^b\)      | Stokes et al\(^23\)        |
| 45–64 y                                             | Beta Pert         | 0.186          | 0.168-0.2047\(^b\)      | Stokes et al\(^23\)        |
| ≥65 y                                               | Beta Pert         | 0.148          | 0.133-0.163\(^b\)       | Stokes et al\(^23\)        |
| **Probability of mortality**                        |                   |                |                         |                             |
| 0–17 y                                              | Beta Pert         | 0.022          | 0.019-0.024\(^b\)       | Stokes et al\(^23\)        |
| 18–44 y                                             | Beta Pert         | 0.075          | 0.067-0.082\(^b\)       | Stokes et al\(^23\)        |
| 45–64 y                                             | Beta Pert         | 0.208          | 0.187-0.228\(^b\)       | Stokes et al\(^23\)        |
| ≥65 y                                               | Beta Pert         | 0.607          | 0.546-0.668\(^b\)       | Stokes et al\(^23\)        |
| Pneumonia, given hospitalization                    | Beta              | 0.79           | 0.711-0.869\(^d\)       | Guan et al\(^24\)          |
| ARDS, requiring ventilator use in ICU               | Beta              | 0.771\(^a\)    | 0.053                   | Arentz et al\(^25\),       |
|                                                     |                   |                |                         | Richardson et al\(^26\),   |
|                                                     |                   |                |                         | Gold et al\(^27\),         |
|                                                     |                   |                |                         | Bhatraju et al\(^28\),     |
|                                                     |                   |                |                         | Auld\(^29\)                |
| **Age group, given infection**                      |                   |                |                         |                             |
| 0–17 y                                              | Point estimate    | 0.05           | ...                     | Stokes et al\(^24\)        |
| 18–44 y                                             | Point estimate    | 0.39           | ...                     | Stokes et al\(^24\)        |
| 45–64 y                                             | Point estimate    | 0.33           | ...                     | Stokes et al\(^24\)        |
| ≥65 y                                               | Point estimate    | 0.23           | ...                     | Stokes et al\(^24\)        |
| **Durations, d**                                    |                   |                |                         |                             |
| Ambulatory care                                      | Point estimate    | 0.5            | ...                     | Assumption                 |
| Duration of symptoms with mild illness             | Triangular        | 7              | 3–17                    | Arashito et al\(^10\),     |
|                                                     |                   |                |                         | Duszynski et al\(^11\),    |
|                                                     |                   |                |                         | Chang et al\(^12\)         |
| Duration of symptoms prior to hospital admission   | Triangular        | 7              | 3–9\(^d\)               | Garg et al\(^13\),         |
|                                                     |                   |                |                         | Wang et al\(^14\)          |
| **Hospitalization, not admitted to ICU, age group** |                   |                |                         |                             |
| 0–49 y                                              | Gamma             | 3.9\(^a\)      | 3.7                     | CDC\(^24\)                 |
| 50–64 y                                             | Gamma             | 4.9\(^a\)      | 4.3                     | CDC\(^24\)                 |
| ≥65 y                                               | Gamma             | 6.2\(^a\)      | 5.7                     | CDC\(^24\)                 |

(Continued)
5,904–25,881) respirators for the COVID-19 patients admitted that month (30%–60% COVID-19 admission prevalence). Varying the frequency at which HCWs interact with COVID-19 patients in the ICU up to 4 times more compared to patients in the general ward (ie, 10 encounters between HCWs and COVID-19 patients in the general ward vs 40 encounters per day in ICU) increases the number of respirators required to 12,593 (95% IPR, 6,429–22,725) to 25,327 (95% IPR, 12,923–44,951) as COVID-19 prevalence increases from 30% to 60% in a hospital with 400 all-cause admissions per month (single-use N95).

Figure 2 illustrates how increasing the number of times an N95 respirator is used before discarding reduces the number of respirators a hospital needs for COVID-19 patients. For example, a hospital with 400 all-cause monthly admissions with a 30% COVID-19 admission prevalence (ie, 120 COVID-19 patients in the general ward vs 40 encounters per day in ICU) increases the number of respirators required to 12,593 (95% IPR, 6,429–22,725) to 25,327 (95% IPR, 12,923–44,951) as COVID-19 prevalence increases from 30% to 60% in a hospital with 400 all-cause admissions per month (single-use N95).

Figure 2 also shows the impact of varying the frequency of interactions between HCWs and each COVID-19 patient on the total number of N95s needed. For example, a hospital with 400 admissions per month with a 30% COVID-19 admission prevalence (120 monthly COVID-19 admissions) would require 1,320 (95% IPR, 6,429–22,725) respirators assuming 10 encounters per day between HCWs and each COVID-19 patient in general wards and ICUs. When encounters are 4 times more frequent (25,611; 95% IPR, 12,607–44,117 when ICU visits are 4 times more frequent), the number increases to 12,739 respirators (95% IPR, 6,582–22,353) to 25,492 respirators (95% IPR, 13,073–45,781) when encounters are 4 times more frequent for ICU patients.

Table 1.

| Parameter                               | Distribution Type | Mean or Median | Standard Error or Range | Source                        |
|-----------------------------------------|-------------------|----------------|-------------------------|-------------------------------|
| Hospitalization, ICU (all ages)         | Gamma             | 9              | 4–17                   | Gold et al<sup>27</sup>       |
|                                         |                   |                |                        | Bhatraju et al<sup>28</sup>   |
|                                         |                   |                |                        | Auld et al<sup>29</sup>       |
|                                         |                   |                |                        | Lewnard et al<sup>35</sup>    |
| Hospitalization, ventilator use         | Gamma             | 9              | 5–12                   | Gold et al<sup>27</sup>       |
|                                         |                   |                |                        | Bhatraju et al<sup>28</sup>   |
|                                         |                   |                |                        | Imam et al<sup>36</sup>       |

Note. CDC, Centers for Disease Control and Prevention; ICU, intensive care unit; ARDS, acute respiratory distress syndrome.

<sup>a</sup>Mean.

<sup>b</sup>Values are ±10% of median value.

<sup>c</sup>Values are interquartile range.

<sup>d</sup>Values are 10%–90%.

Fig. 1. Number of N95 respirators needed in an acute-care hospital in the United States as the prevalence of COVID-19 among hospital admissions increases when there are (A) 10 encounters per day between healthcare workers (HCWs) and COVID-19 patients in general wards and ICUs and when there are (B) 10 encounters per day between HCWs and COVID-19 patients in general wards and 40 encounters per day with COVID-19 patients in ICUs.

![Graph showing the number of N95 respirators needed](https://www.cambridge.org/core).
ICU visits are 4 times more frequent), assuming that each N95 is used once before being discarded.

**N95 respirators needed for COVID-19 admissions nationally over the course of the pandemic**

Table 2 shows how the total number of N95 respirators needed changes as the COVID-19 pandemic progresses and more people get infected (ie, as the attack rate increases). For example, if 20% of the US population become infected with SARS-CoV-2 (ie, 20% attack rate) over the course of the pandemic, there would be a median of 42.5 million (95% IPR, 40.9–44.1 million) symptomatic COVID-19 cases and 33.1 million (95% IPR, 13.5–79.0 million) hospital bed days. Assuming single-use N95 respirators and 10 HCW-patient encounters per day, the United States would require a total of 343.8 million (95% IPR, 145.5–806.7 million) N95 respi-
rators. At a higher attack rate (50%), there would be 106.3 million (95% IPR, 102.3–110.3 million) symptomatic cases and 82.8 million (95% IPR, 33.7–197.5 million) hospital bed days, requiring 860 million (95% IPR, 370.7 million–2.0 billion) N95s in the United States under single-use guidelines.

Figure 3 shows how varying the number of N95 respirator uses and encounters between HCWs and each COVID-19 patient changes as the COVID-19 pandemic progresses and more people get infected (ie, as the attack rate increases).

Fig. 2. Number of N95 respirators needed in an acute-care hospital when varying respirator use guidelines, increasing the number of patient encounters for which a given respirator can be used for various example number of COVID-19 patient admissions per month (ie, for various all-cause admissions and COVID-19 prevalence values). The lower bound of the band represents the minimum number needed when healthcare worker (HCW)–patient interactions are the same for COVID-19 patients in the general ward and ICU. The upper bound represents the maximum number needed when HCW–patient interactions are 4 times higher for ICU patients compared to general ward patients. Note difference in scales across panels.
Table 2. Clinical Outcomes and N95 Respirators (in Millions) Needed Nationally Across Different Attack Rates

| Outcome                  | 5%                  | 20%                  | 50%                  | 90%                  |
|--------------------------|---------------------|----------------------|----------------------|----------------------|
| Symptomatic cases        | 10.6 (10.2–11.0)    | 42.5 (40.9–44.1)     | 106.3 (102.3–110.3)  | 191.4 (184.1–198.5)  |
| Hospitalizations         | 1.5 (1.4–1.6)       | 5.9 (5.5–6.3)        | 14.7 (13.9–15.7)     | 26.5 (25.0–28.2)     |
| GW bed days              | 6.1 (1.6–16.9)      | 24.2 (6.3–67.5)      | 60.6 (15.7–168.9)    | 109.1 (28.3–303.9)   |
| ICU bed days             | 2.3 (0.9–4.9)       | 9.0 (3.8–19.8)       | 22.6 (9.4–49.4)      | 40.6 (16.9–89.0)     |
| Total hospital bed days  | 8.3 (3.4–19.8)      | 33.1 (13.5–79.0)     | 82.8 (33.7–197.5)    | 149.1 (60.6–355.5)   |

N95 respirators needed when HCWs interact with COVID-19 ICU patients at different rates than GW patients

| 10 encounters for GW patients and 10 encounters for ICU patients | 10 encounters for GW patients and 20 for ICU patients | 10 encounters for GW patients and 40 for ICU patients |
|-----------------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------|
| 86.0 (37.1–200.6)                                               | 112.0 (53.2–228.7)                                   | 160.5 (80.2–295.7)                                   |
| 343.8 (145.5–806.7)                                             | 447.7 (213.8–921.6)                                  | 642.6 (321.7–1,186.9)                                |
| 860.0 (370.7–2,006.0)                                           | 1,119.7 (532.1–2,286.8)                             | 1,605.2 (802.5–2,956.5)                              |
| 1,548.0 (667.3–3,610.8)                                         | 2,015.4 (957.8–4,116.2)                             | 2,889.4 (1,444.5–5,321.7)                            |

Note. GW, general ward; ICU, intensive care unit; HCW, healthcare worker.

*Assumes 10 healthcare worker to patient encounters per day and that each N95 respirator is used only once.

Fig. 3. Total number of N95 respirators needed nationally in the United States when varying respirator use guidelines, increasing the number of patient encounters for which a given respirator can be used for various example attack rates (ie, when various proportions of the population get infected with COVID-19 coronavirus) over the course of the pandemic. The lower bound of the band represents the minimum number needed when healthcare worker (HCW)–patient interactions are the same for the general ward and ICU. The upper bound represents the maximum number needed when HCW–patient interactions are 4 times the number for ICU patients compared to general ward patients. Note difference in scales across panels.
influences the number of N95 respirators needed and how this varies with attack rate. For example, allowing respirators to be used for 5 patient interactions before being discarded would require 17.4 million respirators at a 5% attack rate, assuming that HCWs have 10 encounters per day with each COVID-19 patient, and 173.5 million respirators at a 50% attack rate. Figure 3 also shows how the number of encounters influences the number of respirators needed during the course of the pandemic and how this varies with attack rate. The number of N95 respirators needed increases linearly with increases in the number of encounters per day. For example, when each N95 is used for only 1 encounter, if HCWs have 20 encounters with a COVID-19 patient per day (compared to 10), the number of N95 respirators needed nationwide is 172.7 million (95% IPR, 74.6–405.7 million) with a 5% attack rate and 1.7 billion (95% IPR, 0.7–4.1 billion) with a 50% attack rate.

The number of respirators needed also varies with healthcare usage (eg, varying length of stay and the probability of health outcomes resulting in hospitalization). For example, decreasing the probability of hospitalization and ICU admission by a relative 50% results in 158.2 million (95% IPR, 60.6–379.6 million) total N95 respirators needed, while increasing these probabilities by a relative 50% increases the number of total needed to 565.4 million (95% IPR, 261.2 million–1.2 billion) when N95 respirators are used for 1 encounter each (20% attack rate; 10 HCW–patient encounters per day). When decreasing or increasing hospital length of stay by a relative 50%, the number of a respirators needed ranges from 180.0 million (95% IPR, 81.3–397.2 million) to 510.3 million (95% IPR, 214.1 million–1.2 billion) when N95 respirators are used for 1 encounter each before discarding (20% attack rate; 10 HCW–patient encounters per day).

Discussion

Our results demonstrate that there are many conditions under which a single acute-care hospital may require thousands of N95 respirators for HCWs to manage COVID-19 patients admitted in a given month. For hospitals with 400–2,000 all-cause admissions per month (which tend to be mid-to-larger hospitals in size or those with high patient turn over) with a high prevalence of COVID-19 among admissions (eg, 60%), the number of N95 respirators needed could be in the tens of thousands for a single acute-care hospital setting. In light of increasing COVID-19 infections, and reports from 3M that the demand is more than the entire industry can supply for the foreseeable future, it is critical to improve the supply of these respirators, potentially by broadening the use of the Defense Production Act as supported by the American Medical Association, American Hospital Association, and American Nurses Association. By anticipating the potential magnitude of demand for N95s and how this demand can be affected by different epidemiological circumstances and policies, governments and hospitals can better prepare to meet the demands of this pandemic and future outbreaks.

This study has several limitations. All models, by definition, are simplifications of real life and cannot account for every outcome. Model inputs drew from various sources, and new data on COVID-19 continually emerge. Sensitivity analyses helped determine the impact of uncertainty and variability in the available data. Estimates of the number of patients that are seen per HCW can vary by healthcare facility and circumstance. Additionally, determining when a patient encounter begins and ends is difficult (eg, entering a COVID-19 ward vs caring for a particular patient), which can make estimating the number of respirators needed challenging. Furthermore, this study only accounted for N95 respirator use for hospitalized patients and did not include outpatient settings or congregate settings (eg, nursing homes) because recommendations for N95 respirator usage vary outside intensive care settings with alternative options available. Furthermore, although some hospitals may use different types of respirators (eg, N100s, elastomeric respirators), the extent to which these are used is unclear. As such, our analysis focused on the use of N95 respirators. We also focused on the total number of respirators needed at different attack rates regardless of the duration of the outbreak, which would have implications for manufacturing capacity. Finally, our model does not account for the possibility of a single patient becoming
hospitized again for the same COVID-19 infection. Recent CDC estimates indicate ~9% of hospitalized patients are readmitted. In conclusion, our study quantifies the number of N95 respirators needed for a single acute-care hospital and nationally during the COVID-19 pandemic under varying conditions.

Financial support. This work was supported in part by the City University of New York’s Graduate School of Public Health and Health Policy, Agency for Healthcare Research and Quality (AHRQ) (grant no. R01 HS028165-01), and by National Institute of General Medical Sciences (NIGMS) via the Models of Infectious Disease Study (MIDS) network (grant nos. 1 R01 GM127512-01A1 and 3R01GM127512-01A1S1). The funders did not have any role in the study design, collection, analysis, or interpretation of data; writing the report; or the decision to submit the report for publication. Statements in the manuscript do not necessarily represent the official views of, or imply endorsement by, the NIH, AHRQ, or HHS.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References
1. N95 respirators, surgical masks, and face masks 2020. US Food and Drug Administration website. https://www.fda.gov/medical-devices/personal-protective-equipment-infection-control/n95-respirators-surgical-masks-and-face-masks. Accessed January 7, 2021.
2. FAQs on shortages of surgical masks and gowns during the COVID-19 pandemic 2020. US Food and Drug Administration website. https://www.fda.gov/medical-devices/personal-protective-equipment-infection-control/faqs-shortages-surgical-masks-and-gowns-during-covid-19-pandemic. Accessed January 7, 2021.
3. Glenza J. ‘The new gold’: demand for PPE soars again amid shortage as US cases rise The Guardian June 29, 2020.
4. Khazan O. Why we’re running out of masks. The Atlantic April 10, 2020.
5. Toner E. Interim estimate of US PPE needs for COVID-19. Johns Hopkins Center for Health Security, April 18, 2020. Center for Health Security website. https://www.centerforhealthsecurity.org/resources/COVID-19/PPE/PPE-estimate.pdf. Accessed January 7, 2021.
6. Bartsch SM, Ferguson MC, McKinnell JA, et al. Potential health care costs and resource use associated with COVID-19 in the United States. Health Affairs (Project Hope) 2020;39:927–935.
7. Bartsch SM, O’Shea KJ, Ferguson MC, et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. Am J Prev Med 2020. doi: 10.1016/j.amepre.2020.06.011.
8. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. Morb Mortal Wkly Rep 2020;69:759.
9. Goodliffe L, Ragan K, Larocque M, et al. Rate of healthcare worker–patient interaction and hand hygiene opportunities in an acute-care setting. Infect Control Hosp Epidemiol 2014;35:225–230.
10. Implementing filtering facepiece respirator (FFR) reuse, including reuse after decontamination, when there are known shortages of N95 respirators, 2020. Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-n cov/hcp/ppe-strategy/decontamination-reuse-respirators.html. Updated August 4, 2020. Accessed January 7, 2021.
11. Bergman MS, Viscusi DJ, Zhuang Z, Palmiero AJ, Powell JB, Shaffer RE. Impact of multiple consecutive donnings on filtering facepiece respirator fit. Am J Infect Control 2012;40:375–380.
12. Recommended guidance for extended use and limited reuse of N95 filtering facepiece respirators in healthcare settings, 2020. Centers for Disease Control and Prevention website. https://www.cdc.gov/niosh/topics/hcwcontrols/recommendedguidanceextuse.html. Accessed January 7, 2021.
13. National Institute for Occupational Safety and Health. Recommended guidance for extended use and limited reuse of N95 filtering facepiece respirators in healthcare settings, 2020. Centers for Disease Control and Prevention website. https://www.cdc.gov/niosh/topics/hcwcontrols/recommendedguidanceextuse.html. Updated March 27, 2020. Accessed January 7, 2021.
14. N95 mask reuse strategies, 2020. Society of American Gastrointestinal and Endoscopic Surgeons website. https://www.sages.org/n-95-re-use-instructions/. Updated April 17, 2020. Accessed January 7, 2021.
15. Implementing filtering facepiece respirator (FFR) reuse, including reuse after decontamination, when there are known shortages of N95 respirators, 2020. Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/decontamination-reuse-respirators.html. Accessed January 7, 2021.
16. Domestic N95 mask production expected to exceed 1 billion in 2021. US Department of Defense website. https://www.defense.gov/Explore/News/Article/Article/2215532/domestic-n95-mask-production-expected-to-exceed-1-billion-in-2021/. Published 2020. Accessed January 7, 2021.
17. Contrera J. The N95 shortage America can’t seem to fix. The Washington Post September 21, 2020.
18. Pollack RJ, Madara JL, Cole L. AHA, AMA and ANA letter to the president to use DPA for medical supplies and equipment. American Hospital Association website. https://www.aha.org/lettercomment/2020-03-21-aha-ama-and-ana-letter-president-use-dpa-medical-supplies-and-equipment. Published March 21, 2020. Accessed January 7, 2021.
19. Lee BY. Digital decision making: computer models and antibiotic prescribing in the twenty-first century. Revista Cubana de Farmacia 2008;46:1139–1141.
20. Lavery AM, Preston LE, Ko YJ, et al. Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission—United States, March–August 2020. Morb Mortal Wkly Rep 2020;69:1695.
21. COVID-19 pandemic planning scenarios Atlanta, GA: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases, 2020. Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html. Updated May 20, 2020. Accessed June 1, 2020.
22. Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086–5096.
23. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. Morb Mortal Wkly Rep 2020;69:759–765.
24. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.
25. Arenz M, Yim E, Klafl K, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA 2020. doi: 10.1001/ jama.2020.6326.
26. Richardson S, Hirsch JS, Narasimhan M, et al. presenting characteristics, comorbidities, and outcomes among 5,700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020. doi: 10.1001/jama. 2020.6775.
27. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19—Georgia, March 2020. Morb Mortal Wkly Rep 2020;69:545–550.
28. Bhatraju PK, Ghansiehi BJ, Nichols M, et al. COVID-19 in critically ill patients in the Seattle region—case series. N Engl J Med 2020;382:2022–2222.
29. Auld SC, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med 2020. doi: 10.1097/CMM.0000000000004457.
30. Arashiro T, Furukawa K, Nakamura A. COVID-19 in 2 persons with mild upper respiratory symptoms on a cruise ship, Japan. Emerg Infect Dis 2020;26(6). doi: 10.3201/eid2606.200452.
31. Duszynski T. What does it mean to recover from coronavirus? here’s what you need to know. Science Alert Health website. https://www.sciencealert.com/this-is-what-it-means-to-recover-from-corona-and-what-you-can-do-after. Published April 11, 2020. Accessed January 7, 2021.
32. Chang, Mo G, Yuan X, Tao Y, et al. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Respir Crit Care Med 2020. doi: 10.1164/rccm.202003-0524LE.
33. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 states, March 1–30, 2020. Morb Mortal Wkly Rep 2020. doi: 10.15585/mmwr.mm915e3external icon.
34. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020. doi: 10.1001/jama.2020.1585.
35. Lewnard JA, Liu VX, Jackson ML, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. *BMJ* 2020; 369:m1923.
36. Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. *J Intern Med* 2020. doi: 10.1111/joim.13119.